Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Mallinckrodt
Johnson and Johnson
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Brodalumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Brodalumab: Patents, clinical trial progress, indications

Brodalumab is an investigational drug.

There have been 15 clinical trials for Brodalumab. The most recent clinical trial was a Phase 3 trial, which was initiated on April 15th 2018.

The most common disease conditions in clinical trials are Psoriasis, Hidradenitis Suppurativa, and Hidradenitis. The leading clinical trial sponsors are Amgen, LEO Pharma, and Florida Academic Dermatology Centers.

There are seven US patents protecting this investigational drug and one hundred and thirty-four international patents.

Recent Clinical Trials for Brodalumab
TitleSponsorPhase
Biomarkers In Hidradenitis Suppurativa Participants Receiving BrodalumabValeant PharmaceuticalsEarly Phase 1
Biomarkers In Hidradenitis Suppurativa Participants Receiving BrodalumabRockefeller UniversityEarly Phase 1
Treatment of Moderate Hidradenitis SuppurativaOrtho DermatologicsPhase 2

See all Brodalumab clinical trials

Clinical Trial Summary for Brodalumab

Top disease conditions for Brodalumab
Top clinical trial sponsors for Brodalumab

See all Brodalumab clinical trials

US Patents for Brodalumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Brodalumab   Start Trial Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies InCube Labs, LLC (San Jose, CA)   Start Trial
Brodalumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Brodalumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Brodalumab   Start Trial Meditopes and meditope-binding antibodies and uses thereof City of Hope (Duarte, CA)   Start Trial
Brodalumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Brodalumab   Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY)   Start Trial
Brodalumab   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Brodalumab

Drugname Country Document Number Estimated Expiration Related US Patent
Brodalumab Australia 2015258859 2034-05-15   Start Trial
Brodalumab Australia 2016257813 2034-05-15   Start Trial
Brodalumab Australia 2016261599 2034-05-15   Start Trial
Brodalumab Australia 2016320867 2034-05-15   Start Trial
Brodalumab Canada 2949236 2034-05-15   Start Trial
Brodalumab Canada 2983337 2034-05-15   Start Trial
Brodalumab Canada 2984422 2034-05-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Colorcon
Baxter
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.